Valuation: Quest PharmaTech Inc.

Market Cap 33.83L 24.1L 21.62L 19.99L 18.11L 23Cr 34.23L 2.39Cr 95.2L 12Cr 90.44L 88.53L 38Cr P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 43.68L 31.12L 27.92L 25.82L 23.38L 30Cr 44.21L 3.09Cr 1.23Cr 16Cr 1.17Cr 1.14Cr 49Cr EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
Current month-20.00%
1 month-20.00%
3 months-20.00%
6 months-33.33%
Current year-42.86%
1 month 0.02
Extreme 0.02
0.02
Current year 0.02
Extreme 0.02
0.04
1 year 0.02
Extreme 0.02
0.05
3 years 0.02
Extreme 0.015
0.07
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 17/06/2004
Director of Finance/CFO - 01/01/2005
Director TitleAgeSince
Director/Board Member - 17/06/2004
Chairman - 05/07/2021
Director/Board Member - 05/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
12/12/25 OtherCompany 0 0% -
21/10/25 Other

Chief Executive Officer

10,00,000 0.5913%
21/10/25 Other

Chief Executive Officer

3,00,000 0.1774%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-50.00%-69.23% 24.1L
+0.65%-3.36%+36.98%+60.50% 6.41TCr
+1.76%+1.27%+11.82%+81.21% 5.55TCr
-0.94%+0.99%+10.45%+100.19% 5.3TCr
+2.76%+0.87%+27.92%+55.07% 4.6TCr
+2.00%-3.39%+17.83%+119.04% 4.25TCr
+1.34%-2.86%+224.43%+914.08% 4.04TCr
+0.64%-3.95%+11.15%+45.57% 3.23TCr
+29.06%+47.63%+107.12%+92.73% 3.45TCr
-2.55%-0.35%+23.29%-10.69% 2.42TCr
Average +3.46%+3.67%+42.10%+138.85% 3.93TCr
Weighted average by Cap. +3.35%+3.49%+49.21%+159.65%

Financials

2025 2026
Net sales - -
Net income -18.01L -12.83L -11.51L -10.64L -10L -12Cr -18.23L -1.27Cr -50.69L -6.4Cr -48.15L -47.14L -20Cr 49.98L 35.61L 31.95L 29.54L 26.75L 34Cr 50.59L 3.53Cr 1.41Cr 18Cr 1.34Cr 1.31Cr 56Cr
Net Debt 8L 6L 5L 5L 4L 5.39Cr 8L 56.17L 22.37L 2.82Cr 21.25L 20.8L 8.96Cr 10L 7L 6L 6L 5L 6.69Cr 10L 69.65L 27.74L 3.5Cr 26.35L 25.8L 11Cr
Projected Income Statement - Annual - Quest PharmaTech Inc.
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume